DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0135361 A1 Lin Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0135361 A1 Lin Et Al US 2014O135361A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0135361 A1 Lin et al. (43) Pub. Date: May 15, 2014 (54) ANT-ALLERGY (57) ABSTRACT BENZOCYCLOHEPTATHOPHENE The present invention provides inhibitors of allergy, and aller DERVATIVES gic reactions specifically compounds of the present invention are described by the following chemical Formula I: (76) Inventors: Tongjun Lin, Fuzhou City (CN); Jun XIN, Dartmouth (CA) Formula I (21) Appl. No.: 14/129,766 (22) PCT Filed: Jun. 27, 2012 (86) PCT NO.: PCT/CN2012/077591 S371 (c)(1), (2), (4) Date: Dec. 27, 2013 Related U.S. Application Data (60) Provisional application No. 61/502,066, filed on Jun. 28, 2011. ls R-R3 Publication Classification A method for treating an allergic reaction, or allergy diseases (51) Int. C. or disorders includes administering a therapeutically effec CO7D 409/4 (2006.01) tive composition comprising a compound of Formula I or a (52) U.S. C. pharmaceutically acceptable salt, Solvate or prodrug thereof CPC .................................... C07D409/14 (2013.01) and a pharmaceutically acceptable carrier, vehicle or excipi USPC ........................................... 514/318; 546/194 ent to a subject in need thereof. Patent Application Publication May 15, 2014 Sheet 1 of 4 US 2014/O135361 A1 FIG 1A Day 1 Day 3 Day 2 Measurement of Anti-DNPlgE DNFB tissue swelling | V | V | V | {A. 2 Compound A(1 mg/kg. p.O.) Ketotifen (1 mg/kg. p.o.) FIG. 1B Earswelling Foot swelling S. w- & . E C 3. 3. &. 5CD 9d d as 2 O s % s s p s E & E & Š H Šiš. H Š w W Š & sgs & s SS S SSS C S CS& FIG. 2A Collecting ear tissue Anti-DNPlgE (30 min after injection (24 hrs before DNP-Evan's blue of DNP) injection of DNP) Compound A(1 mg/kg. p.o.) Ketotifen (1 mg/kg. p.o.) Patent Application Publication May 15, 2014 Sheet 2 of 4 US 2014/O135361 A1 FIG. 2B Evan's blue dye leakage FIG. 3A Anti-DNPlgE(24 hrs before SS measurementitement Oof application of DNFB) tissue swelling 3 hrs after application of DNFB Compound A(1 mg/kg. p.o.) Ketotifen (1 mg/kg. p.o.) Patent Application Publication May 15, 2014 Sheet 3 of 4 US 2014/O135361 A1 FIG. 3B d o Weight of ear O 2 gas$* Earswelling d) 2is 88 & - 13% Š SE(6 E so 5, 2 six s 9 :8:, . d 9 S is |. S. S. ii. s. gk- is ls. SSSS & sixxYMYYYY Ye'O Untreated Ketotifen Compound -- Untreated Ketotifen Compound A es s g CD2 & Foot swelling wa8 E S.S. s. Weicht9 Of foot E C. S g 5 of 338. w- E 3& r O 5 SE8 - $8 SS f a wa&-8 S sis. & Š aša 5. Untreated Ketotifen Compound Untreated Ketotifen Compound A FIG. 4 E 880 a. Š s S. 3: s s 1 Š Š S Š S S . Š S. S. O ( ). I 19 OG Ketotifen (uM) Compound A (uM) Patent Application Publication May 15, 2014 Sheet 4 of 4 US 2014/O135361 A1 FIG. 5 3ts - Ketotifen e Compound A S. 2000 1500 St O Xava Vava Va a o 5 it an US 2014/O 135361 A1 May 15, 2014 ANT-ALLERGY they need to be administered 3 to 4 times a day. Second, they BENZOCYCLOHEPTATHOPHENE are highly lipophilic and easily cross the blood-brain barrier DERVATIVES causing a major side effect of sedation. Thus, major efforts have been made to improve H1 antihistamine agents by BACKGROUND reducing their side effects on central nervous system and by 0001. The statements in this section merely provide back enhancing the duration of drug effect. ground information related to the present disclosure and may 0007 Accordingly, there is a need for newer anti-allergy not constitute prior art. agents aimed at improved efficacy and reduced side effects. 0002 Allergy is a complex disease. Multiple immune cells and inflammatory mediators contribute to the initiation and SUMMARY manifestation of allergic diseases. In addition to the blockade 0008. The following only summarizes certain aspects of of histamine H1 receptor, the anti-inflammatory effects have the invention and is not intended to be limiting in nature. increasingly been recognized to play an important role in the These aspects and other aspects and embodiments are management of allergic diseases. The anti-inflammatory described more fully below. All references cited in this speci effects include stabilization of mast cells (to prevent mediator fication are hereby incorporated by reference in their entirety. release), blockade of lipid mediators such as platelet-activat In the event of a discrepancy between the express disclosure ing factor (PAF) and leukotrienes, inhibition of adhesion of this specification and the references incorporated by refer molecules, and inhibition of eosinophils and CD4 T cells. ence, the express disclosure of this specification shall control. 0003 Allergic diseases have reached epidemic propor 0009. The invention comprises compounds of Formula I tions worldwide. Allergic diseases such as asthma, rhinitis or that inhibit histamine and allergic reactions and pharmaceu atopic dermatitis affect at least 8%–16% population with the tical compositions thereof. The invention is also directed to annual economic burden of 12.7, 1.2, and 3.8 billion dollars, methods of inhibiting allergic hypersensitivity and for treat respectively, in the United States and are a major health ing allergy, or allergic conditions or diseases in a subject in burden world-wide. The range of allergic diseases includes need thereof. rhinitis, sinusitis, conjunctivitis, asthma, dermatitis and food allergy. These diseases negatively impact the patient’s quality 0010. A first aspect of the invention provides a compound of life and impair their ability to perform in school or work of Formula I: place. Thus, allergic diseases result in significant Socio-eco nomic costs. 0004 Mast cells play a major role in allergy through secre Formula I tion of granule associated and newly synthesized mediators. They are distributed widely in the body and are especially abundant in skin or mucosa where they can interact with foreign materials such as allergens or pathogens. Mast cells possess a large number of high affinity IgE receptors on their Surface. Allergen binding to IgE receptors on mast cells ini tiates a cascade of signaling events leading to the production of potent inflammatory mediators including histamine, plate let-activating factor, IL-6 and many others. 0005 The role of histamine in the pathophysiology of allergic disorders has been well-recognized. Mast cells pro duce and store histamine in their granules. Upon allergen ls R-R3 activation, mast cells immediately (within seconds) release histamine into local tissues. Histamine exerts its effects in allergic diseases primarily through interacting with histamine 00.11 or a pharmaceutically acceptable salt, solvate or H1 receptors which are present in a variety of organs such as prodrug thereof, wherein nerve endings, blood vessel walls, and airway Smooth 0012 R is each independently Cs alkyl, Cs alkenyl, muscles. Histamine has broad biological effects. Depending Cs alkynyl, alkoxy, alkenoxy, Cao cycloalkyl, Cao het on the location where histamine is released, its biological erocycloalkyl, Cao aryl, Cao aralkyl, aralkyloxy, Cao het effects vary from mild discomfort of itch to life-threatening eroaryl, or Coheteroaralkyl, wherein each Cs alkyl, Cs bronchoconstriction. In the nose or skin, histamine induces alkenyl, C2-s alkynyl, alkoxy, alkenoxy, Cao cycloalkyl, vasodilation and increases vascular permeability leading to Cao heterocycloalkyl, Cao aryl, Cao aralkyl, aralkyloxy, edema and erythema. It stimulates the sensory nerve endings Coheteroaryl, or Coheteroaralkyl optionally including leading to itching or Sneezing. In the lung, histamine pro 1-3 substituents independently selected from Q or Q.: Vokes the bronchial Smooth muscle leading to bronchocon 0013 R is each independently, hydrogen, halo, OH, striction. —CN, NO. —N=O. —NHOQ, —OQ, SOQ, 0006 H1 antihistamine agents play a pivotal role in the —SOQ, —SON(Q) —SON(Q) —N(Q), —C(O) treatment of allergic diseases and are among the most pre OQ, —C(O)O. —C(O)N(O), —C(=NQ)NQ-, scribed medications in the world. Depending on their action —NQC(=NO)NQ-, —C(O)N(O)(OQ), —N(Q)C(O)- on the central nervous system, H1 antihistamines are classi Q, N(Q)C(O)N(O), N(Q)C(O)O-Q, N(Q) fied as first-generation and second-generation. In general, SOO. —N(Q)SOQ, Cisalkyl, C-salkenyl, Cs alkynyl, first-generation H1 antihistamines such as dexchlorphe alkoxy, alkenoxy, Cao cycloalkyl, Cao heterocycloalkyl, niramine, hydroxyZine, contain two features that limit their Cao aryl, Cao aralkyl, aralkyloxy, Cao heteroaryl, or Cao usage. One, they are rapidly absorbed and metabolized. Thus, heteroaralkyl, wherein each Cs alkyl, Cs alkenyl, Cs US 2014/O 135361 A1 May 15, 2014 alkynyl, alkoxy, alkenoxy, Cao cycloalkyl, Cao heterocy benzo-1,3-dioxolyl. pyridine-N-oxide, 1-piperidinyl, 2-pip cloalkyl, Cao aryl, Cao aralkyl, aralkyloxy, Cao het eridinyl, 3-piperidinyl, 4-piperidinyl, N-methyl-piperidinyl, eroaryl, or Coheteroaralkyl optionally Substituted with 1-3 N-ethyl-piperidinyl, N-propyl-piperidinyl, hexahydrothiopy Substituents independently selected from Q or Q.: ranyl, azepanyl, methylazepanyl, tetrahydropyranyl, pip 0014 each Q is independently hydrogen, Cs alkyl, Cs eridinylmethyl, pyridinyl, pyridinylmethyl, tetrahydrothi alkenyl, alkoxy, alkenoxy, Cao cycloalkyl, Cao aryl, Cao opyranyl, dioxolanylmethyl, dioxanylmethyl. N-isopropyl arylalkyl, aralkyloxy, Cao heterocyclic, or Cao heteroaryl piperidinyl, N-butyl-piperidinyl, N-pentyl-piperidinyl, ring, each optionally including 1-3 Substituents indepen N-hexylpiperidinyl, N-cyclohexyl-piperidinyl, N-acetyl-pip dently selected from Q.: eridinyl, or N-benzyl-piperidinyl. In some aspects, R is pyri 0015 each Q is halo, haloalkyl, oxo, oxime, azido, dine. amino, amido, cyano, ON, NO, CF.
Load more

Recommended publications
  • Updates in Pediatric Dermatology
    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
    [Show full text]
  • Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, Or Psoriasis: a Review of Clinical and Cost- Effectiveness
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost- Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: September 25, 2017 Report Length: 19 Pages Authors: Raywat Deonandan, Melissa Severn Cite As: Pimecrolimus for the treatment of adults with atopic dermatitis, seborrheic dermatitis, or psoriasis: a review of clinical and cost- effectiveness. Ottawa: CADTH; 2017 Sep. (CADTH rapid response report: summary with critical appraisal). Acknowledgments: ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • Pimecrolimus Cream 1% PI
    Mat# 238328-01 Filename: 238328-01_PimecroCrm30gPi_5_18.indd Proof# 1 Artist Name/Date: Mike Aspinall 9/10/18 AMT Version: 10 Sep 2018 Vault# VV-141752 Approvals:* NDA/ANDA# 209345 Black Approval: Date: Approval: Date: ” n/a Rev: * Applicable when approver is not able to apply electronic signature to PDF in Veeva Vault or Acrobat® Electronic and scanned proxy approval signatures appear on separate pages following the proof pages within this PDF Iss. 5/2018 n/a Created by: Outsert Configuration: Regulatory Affairs US Artwork Management Team Flat: 10” x 27” 1070 Horsham Road, North Wales, PA, 19454 Phone 215-591-3000 Fold: 5” x 2.25” Die Line - No Print 10” 10.00 1/8” 5” 5” 2.25” .25” 238328-01 238328-01 Pimecrolimus Cream Pimecrolimus Cream Rx only Rx only 238328-01 238328-01 Iss. 5/2018 Iss. 5/2018 HIGHLIGHTS OF PRESCRIBING INFORMATION • If signs and symptoms persist beyond 6 weeks, patients should be 8 USE IN SPECIFIC POPULATIONS These highlights do not include all the information needed to use re-examined. (2) 8.1 Pregnancy PIMECROLIMUS CREAM safely and effectively. See full prescribing • Continuous long-term use of pimecrolimus cream, 1% should be Pregnancy Category C information for PIMECROLIMUS CREAM. avoided. (2) There are no adequate and well-controlled studies with pimecrolimus cream, 1% in pregnant women. Therefore, pimecrolimus cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. PIMECROLIMUS cream, 1% for topical use • Avoid use with occlusive dressings. (2) Initial U.S. Approval: 2001 In dermal embryofetal developmental studies, no maternal or fetal toxicity was observed up to the highest practicable doses tested, 10 mg/kg/day DOSAGE FORMS AND STRENGTHS ”2 (1% pimecrolimus cream) in rats (0.14X MRHD based on body surface area) and 10 mg/kg/day (1% pimecrolimus cream) in rabbits (0.65X MRHD WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN Cream, 1%.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Evidence-Based Danish Guidelines for the Treatment of Malassezia- Related Skin Diseases
    Acta Derm Venereol 2015; 95: 12–19 SPECIAL REPORT Evidence-based Danish Guidelines for the Treatment of Malassezia- related Skin Diseases Marianne HALD1, Maiken C. ARENDRUP2, Else L. SVEJGAARD1, Rune LINDSKOV3, Erik K. FOGED4 and Ditte Marie L. SAUNTE5; On behalf of the Danish Society of Dermatology 1Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, 2 Unit for Mycology, Statens Serum Institut, 3The Dermatology Clinic, Copen- hagen, 4The Dermatology Clinic, Holstebro, and 5Department of Dermatology, Roskilde Hospital, University of Copenhagen, Denmark Internationally approved guidelines for the diagnosis including those involving Malassezia (2), guidelines and management of Malassezia-related skin diseases concerning the far more common skin diseases are are lacking. Therefore, a panel of experts consisting of lacking. Therefore, a panel of experts consisting of dermatologists and a microbiologist under the auspi- dermatologists and a microbiologist appointed by the ces of the Danish Society of Dermatology undertook a Danish Society of Dermatology undertook a data review data review and compiled guidelines for the diagnostic and compiled guidelines on the diagnostic procedures procedures and management of pityriasis versicolor, se- and management of Malassezia-related skin diseases. borrhoeic dermatitis and Malassezia folliculitis. Main The ’head and neck dermatitis’, in which hypersensi- recommendations in most cases of pityriasis versicolor tivity to Malassezia is considered to be of pathogenic and seborrhoeic dermatitis include topical treatment importance, is not included in this review as it is restric- which has been shown to be sufficient. As first choice, ted to a small group of patients with atopic dermatitis. treatment should be based on topical antifungal medica- tion.
    [Show full text]
  • The Rx Consultant Index to Volume XVIII (2009 Issues)
    The Rx Consultant Index to Volume XVIII (2009 Issues) January Number 1 - Prostate Cancer, An Update on Disease Pathogenesis and Drug Therapy An overview of prostate cancer including risk factors, screening recommendations, symptoms, and diagnosis. Sum- marizes treatment options for early and advanced stages. Focuses on the hormonal therapies (luteinizing hormone- hormone-releasing hormone [LHRH] agonists and antiandrogens) that are typically used for both localized prostate cancer and more advanced cancer. The role of bisphosphonate therapy for bone loss or fracture prevention is discussed. Drugs included in this issue: LHRH Agonists Antiandrogens Bisphosphonates leuprolide acetate (Lupron®, Lupron® Depot, Eligard®) bicalutamide (Casodex®) alendronate (Fosamax®, generic) leuprolide acetate implant (Viadur®) flutamide (Eulexin®) zoledronic acid (Zometa®) ® ® goserelin acetate implant (Zoladex ) nilutamide (Nilandron ) Chemotherapy ( ®) ® histrelin acetate implant Vantas docetaxol (Taxotere ) ® ® triptorelin pamoate (Trelstar Depot, Trelstar LA ) mitoxantrone (Novantrone®) February Number 2 - Adult Immunizations The benefits of a pharmacy-based adult immunization program are discussed along with key steps for implementation. Recommended adult vaccines are reviewed with a focus on those commonly administered by pharmacists. Topics cov- ered include the rationale for vaccination, current indications, side effects, precautions, administration schedules, and vaccine questions commonly asked by patients. Vaccines reviewed in this issue: Influenza
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • ELIDEL* (Pimecrolimus)
    PRODUCT MONOGRAPH PrELIDEL* (Pimecrolimus) Cream, 1% Topical Calcineurin Inhibitor Valeant Canada LP Date of Preparation: 2150 St-Elzear Blvd. West November 3, 2011 Laval, Quebec H7L 4A8 Canada Address updated: September 4, 2014 Control No. 150801 * is a registered trademark of Meda Pharma sarl used under license by Valeant 1 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION .....................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................3 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION ..............................................................................11 OVERDOSAGE ................................................................................................................12 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................13
    [Show full text]
  • List of Formulary Drug Removals
    July 2021 Formulary Drug Removals Below is a list of medicines by drug class that have been removed from your plan’s formulary. If you continue using one of the drugs listed below and identified as a Formulary Drug Removal, you may be required to pay the full cost. If you are currently using one of the formulary drug removals, ask your doctor to choose one of the generic or brand formulary options listed below. Category Formulary Drug Formulary Options Drug Class Removals Acromegaly SANDOSTATIN LAR SOMATULINE DEPOT SIGNIFOR LAR SOMAVERT Allergies dexchlorpheniramine levocetirizine Antihistamines Diphen Elixir RyClora CARBINOXAMINE TABLET 6 MG Allergies BECONASE AQ flunisolide spray, fluticasone spray, mometasone spray, DYMISTA Nasal Steroids / Combinations OMNARIS QNASL ZETONNA Anticonvulsants topiramate ext-rel capsule carbamazepine, carbamazepine ext-rel, clobazam, divalproex sodium, (generics for QUDEXY XR only) divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, rufinamide, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT, XCOPRI BANZEL SUSPENSION clobazam, lamotrigine, rufinamide, topiramate, TROKENDI XR ONFI SABRIL vigabatrin ZONEGRAN carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium
    [Show full text]
  • A New Treatment for Seborrheic Dermatitis
    Pimecrolimus: A New Treatment for Seborrheic Dermatitis Charles E. Crutchfield III, MMB, MD Seborrheic dermatitis is a chronic recurrent involved in the inflammatory response. Specifically, inflammatory skin condition that mainly affects pimecrolimus inhibits calcineurin, a calcium- areas containing sebaceous glands. I present a dependent phosphatase enzyme. As a result, macrolac- case of a novel effective topical nonsteroidal tam immunomodulators also are known as calcineurin treatment (pimecrolimus 1.0% cream) for facial inhibitors. Calcineurin is essential in activating a seborrheic dermatitis. Pimecrolimus is a member nuclear transcription factor of activated T cells—a of a new class of nonsteroidal agents— factor that enhances production of many of the macrolactam immunomodulators. cytokines involved in the inflammatory response. Pimecrolimus seems to not produce the side effects eborrheic dermatitis is a chronic recurrent common with chronic use of topical steroids.7,8 inflammatory skin condition that affects the S nasolabial folds, ears, eyebrows, scalp (dan- Case Report druff), chest, umbilicus, and other areas containing A 33-year-old man presented with pink-to-red sebaceous glands.1 This condition also may have patches and plaques on the central area of the face hormonal influences—hence the appearance of (including the nasolabial folds) and overlying greasy seborrheic dermatitis on both the scalp in infants scales (Figure 1A). Ear, scalp, and chest involve- younger than 6 months (cradle cap) and on sebum- ment was minimal. The rash, which had been 1-3 1 rich areas in postadolescents. Seborrheic dermati- present intermittently for 1 /2 years, was progressing tis also has been associated with Pityrosporum in severity and frequency and was failing to respond yeasts, AIDS, and neurologic disease.4-6 The course to over-the-counter hydrocortisone 1% cream.
    [Show full text]